Akitsu Hotta

List of Publications by Year in Descending Order

72 papers	4,357 citations	30 h-index	66 g-index
77 ext. papers	5,302 ext. citations	9 avg, IF	5.27 L-index

#	Paper	IF	Citations
72	Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.. *Journal of Controlled Release*, **2022**, 342, 345-361	11.7	7
71	Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. *Nature Communications*, **2021**, 12, 7101	17.4	6
70	Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells. *STAR Protocols*, **2021**, 2, 100965	1.4	0
69	Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells. *Molecular Therapy - Nucleic Acids*, **2021**, 26, 1107-1114	10.7	5
68	Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein. *Stem Cell Reports*, **2021**, 16, 985-996	8	5
67	Characterization of hiPSC-Derived Muscle Progenitors Reveals Distinctive Markers for Myogenic Cell Purification Toward Cell Therapy. *Stem Cell Reports*, **2021**, 16, 883-898	8	14
66	Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. *Nature Biomedical Engineering*, **2021**, 5, 429-440	19	5
65	A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs. *Cell Reports Medicine*, **2021**, 2, 100298	18	1
64	MAGI-2 orchestrates the localization of backbone proteins in the slit diaphragm of podocytes. *Kidney International*, **2021**, 99, 382-395	9.9	6
63	Expression dynamics of HAND1/2 in in vitro human cardiomyocyte differentiation. *Stem Cell Reports*, **2021**, 16, 1906-1922	8	1
62	Contractile Activity of Myotubes Derived from Human Induced Pluripotent Stem Cells: A Model of Duchenne Muscular Dystrophy. *Cells*, **2021**, 10,	7.9	1
61	Development of alternative gene transfer techniques for and gene therapy in a canine model. *Regenerative Therapy*, **2021**, 18, 347-354	3.7	1
60	Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. *Nature Communications*, **2020**, 11, 1334	17.4	83
59	Generation of a transgene-free iPSC line and genetically modified line from a facioscapulohumeral muscular dystrophy type 2 (FSHD2) patient with SMCHD1 p.Lys607Ter mutation. *Stem Cell Research* , **2020**, 47, 101884	1.6	1
58	Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs. *Cell Stem Cell*, **2020**, 26, 251-261.e8	18	56
57	iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. *Stem Cell Reports*, **2020**, 14, 49-59	8	28
56	A novel ADPKD model using kidney organoids derived from disease-specific human iPSCs. *Biochemical and Biophysical Research Communications*, **2020**, 529, 1186-1194	3.4	15

55	-Dependent Renal Cystogenesis in Human Induced Pluripotent Stem Cell-Derived Ureteric Bud/Collecting Duct Organoids. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 2355-2371	12.7	14
54	Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model. *Stem Cell Reports*, **2020**, 15, 80-94	8	14
53	Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. *Cell Stem Cell*, **2019**, 24, 566-578.e7	18	206
52	In Vitro Disease Modeling of Hermansky-Pudlak Syndrome Type 2 Using Human Induced Pluripotent Stem Cell-Derived Alveolar Organoids. *Stem Cell Reports*, **2019**, 12, 431-440	8	43
51	CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. *Nature Communications*, **2019**, 10, 5302	17.4	66
50	Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors. *Biochemical and Biophysical Research Communications*, **2018**, 497, 719-725	3.4	9
49	Srf destabilizes cellular identity by suppressing cell-type-specific gene expression programs. *Nature Communications*, **2018**, 9, 1387	17.4	18
48	Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells. *Scientific Reports*, **2018**, 8, 310	4.9	17
47	Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress. *Stem Cell Reports*, **2018**, 10, 1835-1850	8	22
46	A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4. *Human Molecular Genetics*, **2018**, 27, 4024-4035	5.6	27
45	A 1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. *Blood Advances*, **2018**, 2, 2262-2272	7.8	17
44	Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. *Cell Stem Cell*, **2018**, 23, 850-858.e4	18	69
43	Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. *Biochemical and Biophysical Research Communications*, **2018**, 505, 1097-1102	3.4	10
42	Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells. *Methods in Molecular Biology*, **2018**, 1828, 191-217	1.4	12
41	Transplantation of neurons derived from human iPS cells cultured on collagen matrix into guinea-pig cochleae. *Journal of Tissue Engineering and Regenerative Medicine*, **2017**, 11, 1766-1778	4.4	28
40	Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. *Nucleic Acids Research*, **2017**, 45, e118	20.1	60
39	Reprogramming progeria fibroblasts re-establishes a normal epigenetic landscape. *Aging Cell*, **2017** , 16, 870-887	9.9	28
38	The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. *Science Translational Medicine*, **2017**, 9,	17.5	134

37	Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. *Stem Cells International*, **2017**, 2017, 8765154	5	23
36	An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development. *Stem Cell Reports*, **2016**, 6, 592-606	8	12
35	Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. *Methods*, **2016**, 101, 27-35	4.6	45
34	Natural Killer Cell Activities Against iPSCs-Derived HLA-Knockout Platelets and Megakaryocytes Reveal Perfect Rejection Profiles for Allotransfusion. *Blood*, **2016**, 128, 3841-3841	2.2	2
33	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. *Scientific Reports*, **2016**, 6, 34904	4.9	56
32	Sall1 transiently marks undifferentiated heart precursors and regulates their fate. *Journal of Molecular and Cellular Cardiology*, **2016**, 92, 158-62	5.8	16
31	Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. *Cell Reports*, **2016**, 15, 2301-2312	10.6	101
30	From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. *Annual Review of Genetics*, **2015**, 49, 47-70	14.5	89
29	Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. *Experimental Hematology*, **2015**, 43, 849-57	3.1	36
28	Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. *Stem Cell Reports*, **2015**, 4, 143-154	8	388
27	Comprehensive chemical secretory measurement of single cells trapped in a micro-droplet array with mass spectrometry. *RSC Advances*, **2015**, 5, 16968-16971	3.7	16
26	Genome Editing Gene Therapy for Duchenne Muscular Dystrophy. *Journal of Neuromuscular Diseases*, **2015**, 2, 343-355	5	9
25	Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases. *International Journal of Molecular Sciences*, **2015**, 16, 24751-71	6.3	24
24	Editing Cultured Human Cells: From Cell Lines to iPS Cells **2015**, 45-69		1
23	Genetic correction using engineered nucleases for gene therapy applications. *Development Growth and Differentiation*, **2014**, 56, 63-77	3	34
22	Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. *Stem Cell Reports*, **2014**, 3, 242-9	8	93
21	Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. *PLoS ONE*, **2014**, 9, e104957	3.7	38
20	Hair follicle dermal stem cells regenerate the dermal sheath, repopulate the dermal papilla, and modulate hair type. *Developmental Cell*, **2014**, 31, 543-58	10.2	128

19	Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. *Stem Cell Reports*, **2013**, 1, 283-92	8	196
18	Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. *Scientific Reports*, **2013**, 3, 1978	4.9	35
17	Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. *PLoS ONE*, **2013**, 8, e61540	3.7	150
16	Ataxia-telangiectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to genomic instability in iPS cells. *Biochemical and Biophysical Research Communications*, **2011**, 407, 321-6	3.4	39
15	Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. *Cell Stem Cell*, **2011**, 8, 228-40	18	865
14	Constitutive heterochromatin reorganization during somatic cell reprogramming. *EMBO Journal*, **2011**, 30, 1778-89	13	116
13	Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. *Human Molecular Genetics*, **2011**, 20, 2103-15	5.6	209
12	Chemical Control of iPS Cells. *Trends in the Sciences*, **2011**, 16, 62-65	0	
11	MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. *PLoS ONE*, **2009**, 4, e6810	3.7	55
10	Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. *Nature Methods*, **2009**, 6, 370-6	21.6	234
9	EOS lentiviral vector selection system for human induced pluripotent stem cells. *Nature Protocols*, **2009**, 4, 1828-44	18.8	67
8	Beta-globin LCR and intron elements cooperate and direct spatial reorganization for gene therapy. *PLoS Genetics*, **2008**, 4, e1000051	6	8
7	Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. *Journal of Cellular Biochemistry*, **2008**, 105, 940-8	4.7	131
6	Retrovirus silencing by an epigenetic TRIM. *Cell*, **2007**, 131, 13-4	56.2	22
5	YY1 binds to regulatory element of chicken lysozyme and ovalbumin promoters. *Cytotechnology*, **2006**, 52, 159-70	2.2	2
4	Characterization of transient expression system for retroviral vector production. *Journal of Bioscience and Bioengineering*, **2006**, 101, 361-8	3.3	18
3	Production of anti-CD2 chimeric antibody by recombinant animal cells. *Journal of Bioscience and Bioengineering*, **2004**, 98, 298-303	3.3	9
2	Production of anti-prion scFv-Fc fusion proteins by recombinant animal cells. *Journal of Bioscience and Bioengineering*, **2003**, 95, 231-238	3.3	29